Today: 7 July 2026
Browse Category

NASDAQ:CRNX 26 September 2025 - 7 July 2026

Crinetics spread tightens after Vertex $10B cash offer puts CRNX shares in merger-arb focus

Crinetics spread tightens after Vertex $10B cash offer puts CRNX shares in merger-arb focus

Crinetics Pharmaceuticals Inc jumped from a biotech launch story to a cash deal after Vertex Pharmaceuticals Inc said it will buy the San Diego company for $85 a share. Shares traded at $83.60 as of 4:28 a.m. ET, up 98.9% premarket. The price was $1.40 per share, or 1.7%, away from the offer. On Monday, volume hit 5.42 million shares, or 420% of the 65-day average, before the deal reset the stock.
7 July 2026
··
Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals, Inc. stock slid sharply on Thursday, December 18, 2025, after a regulatory filing revealed a leadership transition involving the company’s Chief Medical and Development Officer. In trading, CRNX fell roughly 8% to around the mid‑$40s, with the day’s range stretching from the low‑$40s to the high‑$40s as investors digested the update. Investing.com For a biotech stock—especially one in the middle of a major product launch and multiple late‑stage trials—management continuity matters. But so do fundamentals: Crinetics is no longer “just” a clinical-stage story. It recently reached a pivotal milestone with its first FDA-approved product, and its pipeline continues to generate catalysts that can move CRNX shares independently of any single executive headline.
18 December 2025
·
Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Even as a possible U.S. government shutdown loomed on Capitol Hill, Wall Street managed a modest rise on September 29, 2025. The tech-heavy Nasdaq Composite climbed about 0.5% on the day reuters.com, with investors largely shrugging off fiscal uncertainty. “Investors are clinging to the positives,” noted one strategist, citing hopes of future interest rate cuts and solid economic data reuters.com. Against this cautiously optimistic backdrop, a handful of individual stocks delivered outsized gains thanks to company-specific catalysts – from blockbuster M&A deals to drug approvals and speculative frenzies. Below, we break down the day’s top gainers on U.S. markets and what drove their explosive moves. Electronic Arts – the gaming giant behind Madden and Battlefield – saw its stock rally dramatically on confirmation of a leveraged buyout deal. EA agreed to be taken private for $55 billion, in what would be the largest LBO ever in dollar terms reuters.com. The investor group is led by Saudi Arabia’s Public Investment Fund along with private equity firm Silver Lake and others, who will pay $210 per share in cash reuters.com reuters.com.
29 September 2025
·····
Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics stock has been volatile but trending upward in 2025, with the recent FDA catalyst propelling it sharply higher. On September 26, 2025, CRNX closed around $45–$46, up roughly +28% in a single day reuters.com. This spike followed the Palsonify approval news and likely a short squeeze, given the high short interest prior to the decision marketbeat.com marketbeat.com. The one-year trading range spans $24.10 – $62.53 marketbeat.com, meaning the stock is now nearly double its 52-week low and about 26% below its 2023 high. In other words, even after the recent surge to the mid-$40s, CRNX trades mid-range of its past year’s spectrum. Year-to-date, CRNX has delivered solid returns outperforming the broader market, as investors anticipated the acromegaly drug approval. The stock’s market capitalization now sits around $4.2–$4.3 billion at the new share price marketbeat.com. Notably, trading volume on Sept. 26 hit ~7–10 million shares as traders and funds rushed to buy on the positive news marketbeat.com. This momentum suggests strong bullish sentiment in the wake of the FDA decision.
26 September 2025
··

Stock Market Today

  • Aehr Test Systems (AEHR) trades above $71.33 analyst target
    July 7, 2026, 8:21 AM EDT. Aehr Test Systems (AEHR) traded up to $72.33, putting the stock ahead of the $71.33 average analyst 12-month target price. That target comes from three analysts with estimates between $56 and $90. Analyst views stay positive: three call it a strong buy, two rate it hold, with no sells on record. Analysts and investors will watch for moves as the stock stays above consensus targets. All figures from Zacks Investment Research and Quandl.com.
Go toTop